Invivyd, Inc.

Invivyd maintains a strong liquidity position with $184.2 million in cash and equivalents against $38.7 million in total liabilities, resulting in a current ratio of 6.47 and a debt-to-equity ratio of 0.0. The company trades at a market capitalization of $188.7 million, representing a price-to-book ratio of 0.93 and an EV/Revenue multiple of 0.08. Despite ample cash reserves, the firm reported a net loss of $41.4 million in Q1 2026, driven by operating losses of $43.1 million. Free cash flow was negative $42.4 million, reflecting operating cash outflows of $41.7 million and capital expenditures of $0.7 million. The balance sheet shows total assets of $241.7 million and total equity of $203.1 million, indicating a capital structure heavily reliant on equity financing rather than debt.

Profitability metrics remain deeply negative, with a return on equity of -25.85% and a return on assets of -21.71%. The company generated $13.7 million in revenue during Q1 2026, but this is insufficient to cover operating costs, leading to an accumulated deficit of $995.9 million. The negative EV/EBITDA of -0.08 underscores the lack of earnings before interest, taxes, depreciation, and amortization. Compared to typical pharmaceutical peers, Invivyd’s financial profile is characteristic of a pre-profitability biotech firm, where value is derived from pipeline potential rather than current earnings. The high cash balance provides a runway for continued operations, but the persistent net losses erode equity over time.

Revenue concentration is high, with the company’s primary income source being its approved product, VYD2311, for COVID-19 treatment. The financial data does not provide a detailed segment breakdown, but the reliance on a single therapeutic area exposes the company to significant market and competitive risks. Geographic exposure is primarily domestic, as indicated by the distribution agreements with U.S.-based specialty distributors. The lack of diversification in both product portfolio and geographic markets amplifies the impact of any decline in demand for its current product or delays in pipeline advancements.

Growth trajectory is uncertain, with Q1 2026 revenue of $13.7 million representing a modest scale of operations. The company has not demonstrated consistent revenue growth, and the focus remains on advancing its pipeline of monoclonal antibody candidates. The historical data shows a pattern of significant cash burn, with operating cash flows consistently negative. The company’s ability to grow revenue will depend on the successful commercialization of new products and the maintenance of market share for VYD2311 in a competitive landscape. The lack of historical revenue trends in the provided data limits the ability to assess long-term growth potential, but the current trajectory suggests a reliance on future product approvals for meaningful revenue expansion.

Risk factors are elevated, with the company facing high dilution risk due to the material difference between basic and diluted share counts (282.8 million basic vs. 309.7 million diluted). Filings reference going-concern or substantial-doubt language, highlighting the uncertainty of the company’s ability to continue as a going concern without additional financing. The company has an active at-the-market (ATM) offering facility and has recently engaged in equity issuances, which contribute to shareholder dilution. The high dilution risk is further exacerbated by the company’s need to raise capital to fund ongoing operations and pipeline development.

Recent events include the company’s continued deficiency in meeting Nasdaq’s minimum bid price requirement of $1.00, with the stock closing below this threshold for 32 consecutive trading days. The company is in a cure period with a deadline of January 18, 2027, to regain compliance. Analyst estimates show a mean price target of $10.00, with a strong buy recommendation from one analyst and buy recommendations from two others, suggesting potential upside if the company’s pipeline progresses successfully. However, the current market price of $0.61 reflects significant skepticism about the company’s near-term prospects.

Analysts project 1,535.6% upside to a $10 target, reflecting strong buy consensus from three analysts.

The company maintains a low leverage band with a debt-to-equity ratio of 0.1463 and no long-term debt.

A current ratio of 7.24 indicates strong short-term liquidity coverage relative to immediate obligations.

Cash conversion of 1.11 exceeds the pharmaceutical cohort median of 0.95, suggesting efficient cash generation.

Net income improved to -$52.5 million in FY2025, showing a reduction in losses compared to prior periods.

High liquidity and dilution risks are flagged, threatening capital stability and existing shareholder value.

Revenue $13.7M; Operating income -$43.1M.

• ▍Revenue $13.7M
• ▍Operating income -$43.1M
• ▍Net margin -301.2%

Revenue $36.2M; Operating income -$43.0M.

• ▍Revenue $36.2M
• ▍Operating income -$43.0M
• ▍Net margin -114.4%

Revenue $23.1M; Operating income -$32.0M.

• ▍Revenue $23.1M
• ▍Operating income -$32.0M
• ▍Net margin -134.0%

Revenue $53.4M; Operating income -$55.6M.

• ▍Revenue $53.4M
• ▍Operating income -$55.6M
• ▍Net margin -98.2%

Revenue $25.4M; Operating income -$176.9M.

• ▍Revenue $25.4M
• ▍Operating income -$176.9M
• ▍Net margin -669.4%

Revenue $25.4M; Operating income -$176.9M.

• ▍Revenue $25.4M
• ▍Operating income -$176.9M
• ▍Net margin -669.4%

Revenue $0.00; Operating income -$212.8M.

• ▍Revenue $0.00
• ▍Operating income -$212.8M

Operating income -$212.8M.

• ▍Operating income -$212.8M